MA32512B1 - Derive de phenanthrenone, compositions et procedes - Google Patents

Derive de phenanthrenone, compositions et procedes

Info

Publication number
MA32512B1
MA32512B1 MA33568A MA33568A MA32512B1 MA 32512 B1 MA32512 B1 MA 32512B1 MA 33568 A MA33568 A MA 33568A MA 33568 A MA33568 A MA 33568A MA 32512 B1 MA32512 B1 MA 32512B1
Authority
MA
Morocco
Prior art keywords
phenanthrenone
derivatives
compositions
processes
compounds
Prior art date
Application number
MA33568A
Other languages
Arabic (ar)
English (en)
Inventor
Paul Vincent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA32512B1 publication Critical patent/MA32512B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention porte sur des composés de formule (i) ou sur les sels de ces composés, qui sont des modulateurs du récepteur des glucocorticoïdes. Les composés et sels de l'invention sont utiles dans le traitement d'états à médiation par l'activité de récepteur des glucocorticoïdes.
MA33568A 2008-07-28 2011-01-28 Derive de phenanthrenone, compositions et procedes MA32512B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28
PCT/IB2009/053044 WO2010013158A1 (fr) 2008-07-28 2009-07-14 Composés de phénanthrénone, compositions et procédés

Publications (1)

Publication Number Publication Date
MA32512B1 true MA32512B1 (fr) 2011-07-03

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33568A MA32512B1 (fr) 2008-07-28 2011-01-28 Derive de phenanthrenone, compositions et procedes

Country Status (38)

Country Link
US (2) US8148409B2 (fr)
EP (1) EP2307375B1 (fr)
JP (1) JP4823397B1 (fr)
KR (1) KR101377860B1 (fr)
CN (1) CN102112446B (fr)
AP (1) AP2744A (fr)
AR (1) AR072535A1 (fr)
AU (1) AU2009278029B2 (fr)
BR (1) BRPI0917212A2 (fr)
CA (1) CA2729578C (fr)
CL (1) CL2011000141A1 (fr)
CO (1) CO6290761A2 (fr)
CR (1) CR20110012A (fr)
CU (1) CU23983B1 (fr)
DK (1) DK2307375T3 (fr)
DO (1) DOP2011000029A (fr)
EA (1) EA018024B1 (fr)
EC (1) ECSP11010795A (fr)
ES (1) ES2527137T3 (fr)
GE (1) GEP20125640B (fr)
GT (1) GT201100026A (fr)
HR (1) HRP20150021T1 (fr)
IL (1) IL210492A (fr)
MA (1) MA32512B1 (fr)
MX (1) MX2011001053A (fr)
NI (1) NI201100028A (fr)
NZ (1) NZ590559A (fr)
PE (1) PE20110559A1 (fr)
PL (1) PL2307375T3 (fr)
PT (1) PT2307375E (fr)
RS (1) RS53747B1 (fr)
SI (1) SI2307375T1 (fr)
SV (1) SV2011003821A (fr)
TW (1) TWI374878B (fr)
UA (1) UA99198C2 (fr)
UY (1) UY32011A (fr)
WO (1) WO2010013158A1 (fr)
ZA (1) ZA201101520B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
JP4100908B2 (ja) 1999-07-30 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 塩基性抗生物質・無機酸塩の製造法およびシュウ酸塩中間体
EP1201649B1 (fr) 2000-10-28 2006-05-31 Pfizer Products Inc. Modulateurs du récepteur corticoide
ES2246292T3 (es) * 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
WO2004005229A1 (fr) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
WO2008064274A1 (fr) 2006-11-21 2008-05-29 Rigel Pharmaceuticals, Inc. Promédicaments de composés de 2,4-pyrimidinediamine et leurs utilisations
EP2121029A2 (fr) 2006-12-05 2009-11-25 Neurogesx, Inc. Promédicaments et procédés pour les fabriquer et les utiliser
UZ4378C (en) * 2007-02-02 2011-07-29 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
DK2114970T3 (da) * 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer

Also Published As

Publication number Publication date
BRPI0917212A2 (pt) 2015-11-10
RS53747B1 (sr) 2015-06-30
US8552035B2 (en) 2013-10-08
TWI374878B (en) 2012-10-21
CN102112446A (zh) 2011-06-29
ECSP11010795A (es) 2011-02-28
CU20110020A7 (es) 2011-12-28
HK1154245A1 (en) 2012-04-13
SI2307375T1 (sl) 2015-02-27
SV2011003821A (es) 2011-07-28
AP2744A (en) 2013-09-30
UY32011A (es) 2010-02-26
ZA201101520B (en) 2011-10-26
US8148409B2 (en) 2012-04-03
CL2011000141A1 (es) 2011-06-17
GT201100026A (es) 2013-12-10
US20100069444A1 (en) 2010-03-18
PT2307375E (pt) 2015-01-14
IL210492A0 (en) 2011-03-31
JP2011529103A (ja) 2011-12-01
EP2307375B1 (fr) 2014-11-19
KR20110022091A (ko) 2011-03-04
DOP2011000029A (es) 2014-07-31
EP2307375A1 (fr) 2011-04-13
CA2729578A1 (fr) 2010-02-04
JP4823397B1 (ja) 2011-11-24
CR20110012A (es) 2011-02-10
AP2011005562A0 (en) 2011-02-28
MX2011001053A (es) 2011-04-21
PL2307375T3 (pl) 2015-03-31
CU23983B1 (es) 2014-03-26
GEP20125640B (en) 2012-09-10
AU2009278029B2 (en) 2012-05-03
AU2009278029A1 (en) 2010-02-04
UA99198C2 (ru) 2012-07-25
HRP20150021T1 (xx) 2015-03-27
TW201014823A (en) 2010-04-16
ES2527137T3 (es) 2015-01-21
NI201100028A (es) 2011-08-05
PE20110559A1 (es) 2011-08-06
NZ590559A (en) 2011-09-30
EA201100080A1 (ru) 2011-08-30
US20120157502A1 (en) 2012-06-21
WO2010013158A1 (fr) 2010-02-04
IL210492A (en) 2015-04-30
CN102112446B (zh) 2012-10-31
EA018024B1 (ru) 2013-04-30
AR072535A1 (es) 2010-09-01
KR101377860B1 (ko) 2014-03-25
CA2729578C (fr) 2014-05-27
CO6290761A2 (es) 2011-06-20
DK2307375T3 (en) 2014-12-08

Similar Documents

Publication Publication Date Title
MY153057A (en) Tryclic compounds,compositions and methods
CY1119780T1 (el) Παραγωγα πυραζολινοδιονης σαν αναστολεις της οξειδασης nadph
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
MY151246A (en) Benzofuranyl derivatives
CY1115952T1 (el) Παραγωγα πυραζολο πυριδινης σαν αναστολεις της οξειδασης nadρη
MY155626A (en) Organic compounds.
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
EA201001639A1 (ru) Композиции и способы их получения и применения
GEP20146003B (en) Benzothiazole derivatives as anticancer agents
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA32508B1 (fr) Composes organiques
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201270302A1 (ru) Безводные формы производных пиридина
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
EA201100080A1 (ru) Фенантреноновые соединения, композиции и способы
BRPI0606783A2 (pt) derivados de imidazol